Ottawa, Ontario, [Aug 30, 2024] — Leynek Medical Inc., the innovative health tech startup behind the ReneCare App, has been named a finalist in the highly competitive Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. This 12-month entrepreneurship program, spearheaded by the Ted Rogers Centre for Heart Research and the University of Toronto's Translational Biology and Engineering Program, provides education, mentorship, and funding opportunities to foster successful cardiovascular startups.
ReneCare: Revolutionizing Symptom Management for Patients The ReneCare App, developed by Leynek Medical, is designed to assist cancer patients in managing their symptoms and the cardiotoxicity often associated with their treatment. By enabling better communication between patients and their healthcare teams from the comfort of their homes, ReneCare is set to transform the standard of care.
"We created Leynek Medical in 2023 after witnessing the inefficiencies and challenges faced by a family member undergoing cancer treatment," said William Jones, CEO and Co-Founder of Leynek Medical. "The existing system, reliant on in-person visits and manual note-taking, proved not only inefficient but also ineffective. Our app addresses these issues by providing an easy-to-use, human-focused platform for symptom tracking and communication."
Addressing Cardiotoxicity with Innovative Technology Certain cancer treatments, such as chemotherapy and radiation, can lead to cardiotoxicity—a condition where the heart muscle is damaged, impairing its function. Studies indicate that approximately 25% of cancer patients develop cardiotoxicity, a condition that is often underreported and thus numbers are underestimated. ReneCare aims to combat this issue by combining symptom assessment scales, mood tracking, and freeform journal entries to provide a comprehensive overview of a patient's health. The app also employs artificial intelligence to automatically identify trends and correlations, serving as a valuable tool for both patients and healthcare providers.
The ECHO Program: A Catalyst for Growth Since joining the ECHO program in the fall of 2023, Leynek Medical has benefited immensely from the program's specialized focus on cardiovascular health and life sciences. "ECHO has been instrumental in helping us refine our business strategy and understanding the complex medical problems we aim to solve," added Jones. "The mentorship and resources provided by ECHO are unparalleled, and we are excited to apply what we've learned to continue our growth."
Looking Ahead: The Future of Leynek Medical With the support of ECHO and other strategic partnerships, Leynek Medical plans to expand its presence in both the US and Canadian markets. The company is currently in discussions with several hospitals to implement the ReneCare app in both research and real-world settings. As the platform evolves, Leynek Medical is committed to continuously integrating feedback from patients and physicians to enhance its offerings.
About ECHO
ECHO is a specialized training program that aims to accelerate the application of cardiovascular innovations from bench to bedside. By providing mentorship, partnership opportunities, and up to $250,000 in funding, ECHO supports the next generation of cardiovascular health entrepreneurs. The program is funded and organized by the Translational Biology and Engineering Program at the University of Toronto and the Ted Rogers Centre for Heart Research, in partnership with the Health Innovation Hub (H2i).
For more information about Leynek Medical and the ReneCare App, please visit www.leynekmedical.com.
Media Contact:
コメント